Journal of Antimicrobial Chemotherapy (2000) 46, 163-170
© 2000 The British Society for Antimicrobial Chemotherapy
Reviews |
The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens
Bristol Centre for Antimicrobial Research and Evaluation, North Bristol NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK
 |
Introduction |
|---|
In vitro pharmacodynamic models of infection are widely used to assess the likely efficacy of various antibacterial dosing regimens against relevant common pathogens. A significant body of data has been accumulated on the pharmacodynamics of fluoroquinolones using such systems, but there are conflicts with data from other in vitro models and with animal and human findings. To ensure clarity in the development of dosing with fluoroquinolones, and to ensure that regimens are optimized in terms of antibacterial effect and/or preventing emergence of resistance, it is important to seek explanations for these divergent findings. In this review we will discuss the methodological and analytical factors involved in pharmacodynamic analyses using in vitro models of infection and how these may affect the conclusions drawn.
The simplest type of experiment using in vitro pharmacodynamic models tests the simulated serum pharmacokinetic profile of a drug at a defined dose against a range of pathogens
|
Notes |
|---|
|
References |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, J. James, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2006; 58(1): 112 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takei, Y. Yamaguchi, H. Fukuda, M. Yasuda, and T. Deguchi Cultivation of Neisseria gonorrhoeae in Liquid Media and Determination of Its In Vitro Susceptibilities to Quinolones J. Clin. Microbiol., September 1, 2005; 43(9): 4321 - 4327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Meagher, A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2061 - 2068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, D. Roberts, A. Waltky, N. Laing, K. Nichol, H. Smith, A. Noreddin, T. Bellyou, and D. J. Hoban Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., May 1, 2002; 49(5): 807 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aviles, C. Falcoz, M. J. Guillen, R. San Roman, F. Gomez De Las Heras, and D. Gargallo-Viola Correlation between In Vitro and In Vivo Activities of GM 237354, a New Sordarin Derivative, against Candida albicans in an In Vitro Pharmacokinetic-Pharmacodynamic Model and Influence of Protein Binding Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2746 - 2754. [Abstract] [Full Text]
|
|
|
|
|
|
C. E. Thorburn and D. I. Edwards The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance J. Antimicrob. Chemother., July 1, 2001; 48(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Honeybourne, D. Banerjee, J. Andrews, and R. Wise Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother., July 1, 2001; 48(1): 63 - 66. [Abstract] [Full Text] [PDF]
|
|